What motivates people with type 2 diabetes mellitus to participate in clinical trials from home?
Abstract Decentralized clinical trials (DCTs), in which all or part of the trial activities are moved to the participants' immediate surroundings, promise to improve trial conduct. However, no evidence is available on what motivates people to participate in DCTs. Our aim was to determine the dr...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.70070 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846156358752141312 |
|---|---|
| author | Julia Kopanz Bart Lagerwaard Magdalena Beran Jorien Veldwijk Julia K. Mader Tina Pöttler Dietrich Tews Diederick E. Grobbee Mira G. P. Zuidgeest the Trials@Home consortium |
| author_facet | Julia Kopanz Bart Lagerwaard Magdalena Beran Jorien Veldwijk Julia K. Mader Tina Pöttler Dietrich Tews Diederick E. Grobbee Mira G. P. Zuidgeest the Trials@Home consortium |
| author_sort | Julia Kopanz |
| collection | DOAJ |
| description | Abstract Decentralized clinical trials (DCTs), in which all or part of the trial activities are moved to the participants' immediate surroundings, promise to improve trial conduct. However, no evidence is available on what motivates people to participate in DCTs. Our aim was to determine the drivers and perceptions for participation in clinical trials with different decentralization levels in persons with type 2 diabetes mellitus. Five focus groups were conducted utilizing the nominal group technique in the Netherlands (n = 1), Germany (n = 1), and Austria (n = 3) with four to six participants per group. The focus groups were analyzed using thematic analysis. Of the 26 participants (10 females, median age: 66 years [IQR: 62–72]) 42% had previously participated in a trial, and almost all had internet access at home (96%). A total of seven main themes regarding participation in clinical trials (location, time investment, contact with healthcare professionals (HCPs), digital technologies, data collection, perceived risk, and motivation) were identified, of which a total of 20 drivers emerged. Perceptions regarding trial participation differed widely among participants, and individual preferences influenced which drivers were considered more important by participants. Flexibility of location and time spent on the trial were identified as the most motivating factors for participation in DCTs. Some drivers, such as digital infrastructure, digital literacy, home visits, personal interaction, and relationship with HCPs were perceived as both enablers and barriers, depending on personal preferences. However, most of the potential barriers regarding DCTs may be resolved by addressing them in the design of future DCTs. |
| format | Article |
| id | doaj-art-0180adef2af0498e8648e17eeabe1dfd |
| institution | Kabale University |
| issn | 1752-8054 1752-8062 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj-art-0180adef2af0498e8648e17eeabe1dfd2024-11-26T07:10:37ZengWileyClinical and Translational Science1752-80541752-80622024-11-011711n/an/a10.1111/cts.70070What motivates people with type 2 diabetes mellitus to participate in clinical trials from home?Julia Kopanz0Bart Lagerwaard1Magdalena Beran2Jorien Veldwijk3Julia K. Mader4Tina Pöttler5Dietrich Tews6Diederick E. Grobbee7Mira G. P. Zuidgeest8the Trials@Home consortiumJulius Center for Health Sciences and Primary Care University Medical Center Utrecht Utrecht the NetherlandsJulius Center for Health Sciences and Primary Care University Medical Center Utrecht Utrecht the NetherlandsCardiovascular Research Institute Maastricht (CARIM), Department of Internal Medicine Maastricht University Maastricht the NetherlandsErasmus School of Health Policy & Management (ESHPM) Erasmus University Rotterdam Rotterdam the NetherlandsDivision of Endocrinology and Diabetology, Department of Internal Medicine Medical University of Graz Graz AustriaDivision of Endocrinology and Diabetology, Department of Internal Medicine Medical University of Graz Graz AustriaMVZ Diabeteszentrum Dr. Tews GmbH Gelnhausen GermanyJulius Center for Health Sciences and Primary Care University Medical Center Utrecht Utrecht the NetherlandsJulius Center for Health Sciences and Primary Care University Medical Center Utrecht Utrecht the NetherlandsAbstract Decentralized clinical trials (DCTs), in which all or part of the trial activities are moved to the participants' immediate surroundings, promise to improve trial conduct. However, no evidence is available on what motivates people to participate in DCTs. Our aim was to determine the drivers and perceptions for participation in clinical trials with different decentralization levels in persons with type 2 diabetes mellitus. Five focus groups were conducted utilizing the nominal group technique in the Netherlands (n = 1), Germany (n = 1), and Austria (n = 3) with four to six participants per group. The focus groups were analyzed using thematic analysis. Of the 26 participants (10 females, median age: 66 years [IQR: 62–72]) 42% had previously participated in a trial, and almost all had internet access at home (96%). A total of seven main themes regarding participation in clinical trials (location, time investment, contact with healthcare professionals (HCPs), digital technologies, data collection, perceived risk, and motivation) were identified, of which a total of 20 drivers emerged. Perceptions regarding trial participation differed widely among participants, and individual preferences influenced which drivers were considered more important by participants. Flexibility of location and time spent on the trial were identified as the most motivating factors for participation in DCTs. Some drivers, such as digital infrastructure, digital literacy, home visits, personal interaction, and relationship with HCPs were perceived as both enablers and barriers, depending on personal preferences. However, most of the potential barriers regarding DCTs may be resolved by addressing them in the design of future DCTs.https://doi.org/10.1111/cts.70070 |
| spellingShingle | Julia Kopanz Bart Lagerwaard Magdalena Beran Jorien Veldwijk Julia K. Mader Tina Pöttler Dietrich Tews Diederick E. Grobbee Mira G. P. Zuidgeest the Trials@Home consortium What motivates people with type 2 diabetes mellitus to participate in clinical trials from home? Clinical and Translational Science |
| title | What motivates people with type 2 diabetes mellitus to participate in clinical trials from home? |
| title_full | What motivates people with type 2 diabetes mellitus to participate in clinical trials from home? |
| title_fullStr | What motivates people with type 2 diabetes mellitus to participate in clinical trials from home? |
| title_full_unstemmed | What motivates people with type 2 diabetes mellitus to participate in clinical trials from home? |
| title_short | What motivates people with type 2 diabetes mellitus to participate in clinical trials from home? |
| title_sort | what motivates people with type 2 diabetes mellitus to participate in clinical trials from home |
| url | https://doi.org/10.1111/cts.70070 |
| work_keys_str_mv | AT juliakopanz whatmotivatespeoplewithtype2diabetesmellitustoparticipateinclinicaltrialsfromhome AT bartlagerwaard whatmotivatespeoplewithtype2diabetesmellitustoparticipateinclinicaltrialsfromhome AT magdalenaberan whatmotivatespeoplewithtype2diabetesmellitustoparticipateinclinicaltrialsfromhome AT jorienveldwijk whatmotivatespeoplewithtype2diabetesmellitustoparticipateinclinicaltrialsfromhome AT juliakmader whatmotivatespeoplewithtype2diabetesmellitustoparticipateinclinicaltrialsfromhome AT tinapottler whatmotivatespeoplewithtype2diabetesmellitustoparticipateinclinicaltrialsfromhome AT dietrichtews whatmotivatespeoplewithtype2diabetesmellitustoparticipateinclinicaltrialsfromhome AT diederickegrobbee whatmotivatespeoplewithtype2diabetesmellitustoparticipateinclinicaltrialsfromhome AT miragpzuidgeest whatmotivatespeoplewithtype2diabetesmellitustoparticipateinclinicaltrialsfromhome AT thetrialshomeconsortium whatmotivatespeoplewithtype2diabetesmellitustoparticipateinclinicaltrialsfromhome |